Motley Fool Press Release.
Geron Corp (GERN) posted $60.1 million in quarterly RYTELO revenue and trimmed its 2026 operating expense outlook, even as it discontinued its Phase III IMpactMF myelofibrosis trial.
With the MF label expansion closed, Geron Corporation will focus on maximizing Rytelo's approved lower-risk MDS indication. I rate the GERN stock as Hold. Click to know more.
Geron (GERN) stock falls as the company halts a late-stage trial for its blood cancer therapy imetelstat, marketed as Rytelo. Read more here.
About This EventGeron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, visits the Nasdaq MarketSite in Times Square to commemorate 30 years of being listed on Nasdaq. In honor of the occasion, Harout Semerjian, President and Chief Executive Officer, rings the Closing Bell.
Presentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced two oral presentations and one poster presentation highlighting imetelstat in patients with lower-risk myelodysplastic syndrome
Geron (NASDAQ:GERN) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
Detailed price information for Fair Isaac and Company (FICO-N) from The Globe and Mail including charting and trades.
Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $
Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen
This is the newest page. Registered accounts read further back.